Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved four drugs for AML in 2017 (Pfizer’s Mylotarg, Novartis’s Rydapt, Agios’s Idhifa, and Jazz’s Vyxeos) and an additional four drugs in 2018 (Agios’s Tibsovo, AbbVie’s Venclexta, Pfizer’s Daurismo, and Astellas’s Xospata).
In light of impressive data for multiple newly approved drugs in AML subpopulations, the treatment paradigm is changing rapidly by shifting toward increasingly targeted and personalized therapies.
- Following the FDA approval of eight drugs for AML since 2017, how do physicians incorporate these additional therapy options into their practices?
- What is the uptake of AbbVie’s Venclexta in patients ineligible for intensive induction? Which Venclexta combinations are prescribed most frequently?
- Is Astellas’s Xospata prescribed for FLT3 mutation-positive patients in the relapsed/refractory setting? How is the drug’s uptake affected by prescribing of other FLT3 inhibitors, including Novartis’s Rydapt in the previously untreated setting or Nexavar in the relapsed/refractory setting?
- What will be the uptake of IDH inhibitors in patients with IDH mutations?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of ~100 hematologist-oncologists in the United States.
Key drugs covered: Venclexta, Xospata, Idhifa, Tibsovo, Vyxeos, Daurismo, Mylotarg, Rydapt.